U 77436
U 77436 is a Renin inhibitory peptide. U 77436 is used in the research of hypertension.
For research use only. We do not sell to patients.
- CAS No.: 128657-36-3
- Formula: C50H76N10O11
- Molecular Weight:993.20
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 400-550 g)[1]
-
Dosage:25 μg/rat (intrapulmonary); 75 μg/rat (intravenous)
-
Administration:intrapulmonary; single dose; intravenous; single dose
-
Result:Achieved total recovery of 104.9% in bile and urine after intravenous administration, with 93.3% recovered in bile and 11.6% recovered in urine.
Achieved total recovery of 53.7% in bile and urine after intrapulmonary administration, with 48.0% recovered in bile and 5.7% recovered in urine.
Reached 52.1% intrapulmonary absorption relative to intravenous recovery.
Showed 63% of 51Cr-labeled dose reached the lungs, with an estimated 81% of the lung-delivered dose absorbed by 10 hours.
Chemical Information
-
CAS No. 128657-36-3
-
Molecular Weight 993.20
-
Formula C50H76N10O11
-
SMILES
[O-][N+]1=CC=CC=C1CNC([C@H]([C@@H](C)CC)NC([C@H](C(C)C)C[C@H](O)[C@H](CC(C)C)NC([C@H](CC2=CN=CN2)N(C)C([C@H](CC3=CC=CC=C3)NC([C@H]4N(CCC4)C(NC(CO)(CO)CO)=O)=O)=O)=O)=O)=O
-
Sequence
{Pro(NHCO-NH-C(CH2OH)3)}-Phe-{His(NCH3)}-Leu{(CHOH-CH2)}-Val-{Ile(NHCH2-C5H4NO)}
-
Sequence Shortening
{Pro(NHCO‑NH‑C(CH2OH)3)}‑F‑{His(NCH3)}-Leu{(CHOH‑CH2)}-V-{Ile(NHCH2-C5H4NO)}
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
U 77436 Related Classifications
HY-P2074 Related Classifications
Powered by Bioz